Frank Condella, president and chief executive officer at Molecular Profiles’ US-based parent company, Columbia Laboratories
Molecular Profiles and XenoGesis have announced a collaboration that will support pharmaceutical and biotech drug developers during the pre-clinical and formulation development stage.
Molecular Profiles’ pharmaceutical development services will be supported by XenoGesis’ expertise in preclinical drug metabolism and pharmacokinetics (DMPK) to give clients a smarter route into formulation development and a better understanding of a compound’s bioavailability.
This strategic alliance will allow the Nottingham-based companies to help drug developers in the initial design and selection of compounds for key DMPK and ADME (absorption, distribution, metabolism and elimination) studies, as well as supporting lead candidates, which have solubility issues during formulation development.
“We are very pleased to have struck this collaboration with the team at XenoGesis,” said Frank Condella, president and CEO at Molecular Profiles’ parent company, Columbia Laboratories.
”We have complementary service offerings that allow us to apply a science-driven, collective approach to overcome the complexities of challenging molecules. It also adds a vital pK service to our enabling technologies package.
“For us, this will build-upon the very successful drug development alliances we already have in place. We can now seamlessly offer a comprehensive service from initial drug discovery through to clinical supplies with best-in-class companies,” concluded Mr Condella.
XenoGesis was founded by its managing director, Richard Weaver PhD, after a 15-year career at AstraZeneca. The company specialises in studying research compounds from a chemical and biological perspective to inform clients on how they will behave in the body.
Dr Weaver commented: “Combining our skills in DMPK with the chemical knowledge at Molecular Profiles will provide a solid platform to support clients. We will be able to give them a better understanding of their compounds during preclinical work, which in turn, will reduce cost and provide a quicker route to market.”